Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

NCT03619213 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

6263

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

AstraZeneca